Find below videos and webinars on myeloma. Click here to check full educational resources materials for all areas of work: myeloma and AL amyloidosis, access, patient evidence and capacity building and advocacy.
Mental Health and psychosocial support with myeloma

Now Playing
Mental Health and psychosocial support with myeloma
Surabhi Chaturvedi, Senior Psychotherapist and Service Lead, ...
Surabhi Chaturvedi, Senior Psychotherapist and Service Lead, Psychotherapy Service, Haemato-Oncology, King's College Hospital NHS Foundation Trust shares

Now Playing
Understanding cure in myeloma
What does “cure” look like in myeloma? Professor Philippe Moreau, ...
What does “cure” look like in myeloma?
Professor Philippe Moreau, President of the International Myeloma Society, and Head of Haematology at the University Hospital of Nantes, France explains the emerging ...concept of cure, why experts believe it is now appropriate to discuss it, and what it could mean for people living with myeloma.
He discusses how advances in treatment, particularly newer immunotherapies used alongside established approaches such as autologous stem cell transplantation, have dramatically improved patient outcomes. The conversation explores the proposed international consensus definition of a cure, including the importance of being off treatment and maintaining minimal residual disease (MRD) negativity for at least five years.
Professor Moreau also explains:
Why sustained MRD negativity is considered a key indicator of long-term disease control
Which treatment approaches may make a cure possible
Why access to the latest therapies varies between countries and affects patient outcomes
Which patients are currently most likely to achieve a cure
Why doctors emphasise hope while recognising that not every patient will achieve the same outcomes
The interview concludes by discussing how continuing advances in myeloma treatment are bringing life expectancy for some patients closer to that of the general population.
Please note: This interview reflects current expert opinion and emerging evidence. A cure is not yet achievable for everyone with myeloma, and treatment decisions should always be discussed with your healthcare team.
0:00 (Understanding cure in myeloma)
1:29 (Can we currently cure myeloma?)
2.51 (How are experts defining cure in myeloma?)
3:41 (Which treatments might help a cure?)
5:55 (Which patients could potentially be cured?)Show More
Professor Philippe Moreau, President of the International Myeloma Society, and Head of Haematology at the University Hospital of Nantes, France explains the emerging ...concept of cure, why experts believe it is now appropriate to discuss it, and what it could mean for people living with myeloma.
He discusses how advances in treatment, particularly newer immunotherapies used alongside established approaches such as autologous stem cell transplantation, have dramatically improved patient outcomes. The conversation explores the proposed international consensus definition of a cure, including the importance of being off treatment and maintaining minimal residual disease (MRD) negativity for at least five years.
Professor Moreau also explains:
Why sustained MRD negativity is considered a key indicator of long-term disease control
Which treatment approaches may make a cure possible
Why access to the latest therapies varies between countries and affects patient outcomes
Which patients are currently most likely to achieve a cure
Why doctors emphasise hope while recognising that not every patient will achieve the same outcomes
The interview concludes by discussing how continuing advances in myeloma treatment are bringing life expectancy for some patients closer to that of the general population.
Please note: This interview reflects current expert opinion and emerging evidence. A cure is not yet achievable for everyone with myeloma, and treatment decisions should always be discussed with your healthcare team.
0:00 (Understanding cure in myeloma)
1:29 (Can we currently cure myeloma?)
2.51 (How are experts defining cure in myeloma?)
3:41 (Which treatments might help a cure?)
5:55 (Which patients could potentially be cured?)Show More

Now Playing
MPE webinar | EHA 2026 highlights
Recording of the webinar given by Dr. Johan Lund, Department of ...
Recording of the webinar given by Dr. Johan Lund, Department of Medicine at Karolinska Institutet in Stockholm, Sweden, to explain the main myeloma and AL amyloidoisos highlights presented at the ...European Hematology Association (EHA) Annual Congress 2026.Show More

Now Playing
EHA2026 | EMN34 clinical trial
Dr. Cyrille Touzeau, University Hospital of Nantes, France, explains ...
Dr. Cyrille Touzeau, University Hospital of Nantes, France, explains for MPE, the results of the phase 2 ERASMM (EMN34) study, which evaluates safety and efficacy of elranatamab as early intervention ...in patients with high-risk smoldering myeloma.
0:00 (Watch now)
0:10 (What is elranatamab? How is it given and what should patients know about its current and potential uses?)
0:18 (What is the ERASMM (EMN34) trial investigating and what are its main results?)Show More
0:00 (Watch now)
0:10 (What is elranatamab? How is it given and what should patients know about its current and potential uses?)
0:18 (What is the ERASMM (EMN34) trial investigating and what are its main results?)Show More

Now Playing
EYMPG webinar Mental health and emotional wellbeing
The European Young Myeloma Patients Group (EYMPG) on behalf of Myeloma ...
The European Young Myeloma Patients Group (EYMPG) on behalf of Myeloma Patients Europe hosted a webinar on mental health and emotional wellbeing. This lecture was given by Mitch Golant, PhD, ...Health Psychologist and Senior Consultant at Cancer Support Community, CA, USAShow More

Now Playing
ASH 2025 | IFM2021 01 trial
Dr.Salomon Manier, University of Lille, France, talks through this ...
Dr.Salomon Manier, University of Lille, France, talks through this teclestameb trial. This study shows that an “all-antibody–based” doublet regimen of teclistamab and daratumumab is highly effective and well-tolerated in elderly ...newly diagnosed myeloma patients.Show More

Now Playing
ASH 2025 | Cobra trial
COBRA is a clinical trial evaluating carfilzomib, lenalidomide and ...
COBRA is a clinical trial evaluating carfilzomib, lenalidomide and dexamethasone (KRd) versus bortezomib, lenalidomide
and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM). Watch this interview with Dr. Dominik ...Dytfeld, lead author of this study that was presented in the American Society of Hematology (ASH), held in Orlando, Florida, US.Show More
and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM). Watch this interview with Dr. Dominik ...Dytfeld, lead author of this study that was presented in the American Society of Hematology (ASH), held in Orlando, Florida, US.Show More

Now Playing
ASH 2025 | LINKER-MM4 trial
Dr. Xavier Leleu, Centre Hospitalier Universitaire de Poitiers, ...
Dr. Xavier Leleu, Centre Hospitalier Universitaire de Poitiers, France, explains the main results of the LINKER-MM4 clinical trial which evaluates safety and efficacy of linvoseltamab as a simplified monotherapy in ...first-line regimen in
newly diagnosed myeloma patients. The initial results of this study were presented at the American Society of Heamtology (ASH) Annual Congress, held in Orlando, Florida, US.Show More
newly diagnosed myeloma patients. The initial results of this study were presented at the American Society of Heamtology (ASH) Annual Congress, held in Orlando, Florida, US.Show More

Now Playing
ASH 2025 | UK MRA FiTNEss trial
The UK MRA FiTNEss trial aims to understand whether the International ...
The UK MRA FiTNEss trial aims to understand whether the International Myeloma Working Group (IMWG) frailty score can be used to tailor treatment according to a myeloma patient’s level of ...fitness. Dr. Charlotte Pawlyn, from The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK, explains the main results of this trial, which were presented at the American Society of Hematology 2025.Show More

Now Playing
ASH25 | Majestec-3 trial
Watch Dr. Charlotte Pawlyn from The Royal Marsden NHS Foundation Trust ...
Watch Dr. Charlotte Pawlyn from The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London, UK, explain the main results of Majestec-3, one of the most important ...myeloma studies presented at the American Society of Hematology (ASH) Annual Congress in Orlando, Florida, US.Show More

Now Playing
ASH 2025 | inMMyCAR trial
Dr. Phoebe Joy Ho from the Royal Prince Alfred Hospital and the ...
Dr. Phoebe Joy Ho from the Royal Prince Alfred Hospital and the University of Sydney, Australia, explains the results of inMMyCAR, a late breaking abstract presented at the American Society ...of Hematology (ASH) Annual Congress, held in Orlando, Florida, US.
The abstracts evaluates Minimal Residual Disease (MRD) negativity following a novel "in vivo" CAR T-cell therapy.Show More
The abstracts evaluates Minimal Residual Disease (MRD) negativity following a novel "in vivo" CAR T-cell therapy.Show More

Now Playing
ASH 2025 | DURGA 1 trial
The Durga-1 trial evaluates safety and efficacy of AZD0120, a ...
The Durga-1 trial evaluates safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma. Dr. Shambavi Richard, Icahn School of Medicine at Mount Sinai, New ...York, United States, explains the main results of the study and its implications for relapsed/refractory myeloma patients.Show More

Now Playing
ASH 2025 | CAMMA 3 clinical trial
Dr. Phoebe Joy Ho, Royal Prince Alfred Hospital and University of ...
Dr. Phoebe Joy Ho, Royal Prince Alfred Hospital and University of Sydney, Australia, explains for Myeloma Patients Europe (MPE) the first results from the phase Ib CAMMA 3 study, in ...which subcutaneous cevostamab shows manageable safety and meaningful clinical activity in relapsed/refractory myeloma (RRMM).
This clinical trial was presented at the American Society of Hematology (ASH) Annual Congress 2025, held in Orlando, Florida, US.Show More
This clinical trial was presented at the American Society of Hematology (ASH) Annual Congress 2025, held in Orlando, Florida, US.Show More

Now Playing
ASH 2025 | NoMoreMGUS
Dr. Bruno Paiva explains the main results of the NoMore MGUS clinical ...
Dr. Bruno Paiva explains the main results of the NoMore MGUS clinical trials presented at the American Society of Hematology (ASH) Annual Congress, in Orlando, Florida, US.

Now Playing
ASH 2025 | GEM-CESAR trial
Dr. Bruno Paiva, Clínica Universidad de Navarra, explains the main ...
Dr. Bruno Paiva, Clínica Universidad de Navarra, explains the main results of the GEM-CESAR clinical trial presented at the American Society of Hematology (ASH), held in Orlando, Florida, US.
1
of 11